Literature DB >> 31255772

RAS mutations in human cancers: Roles in precision medicine.

Avaniyapuram Kannan Murugan1, Michele Grieco2, Nobuo Tsuchida3.   

Abstract

Ras proteins play a crucial role as a central component of the cellular networks controlling a variety of signaling pathways that regulate growth, proliferation, survival, differentiation, adhesion, cytoskeletal rearrangements and motility of a cell. Almost, 4 decades passed since Ras research was started and ras genes were originally discovered as retroviral oncogenes. Later on, mutations of the human RAS genes were linked to tumorigenesis. Genetic analyses found that RAS is one of the most deregulated oncogenes in human cancers. In this review, we summarize the pioneering works which allowed the discovery of RAS oncogenes, the finding of frequent mutations of RAS in various human cancers, the role of these mutations in tumorigenesis and mutation-activated signaling networks. We further describe the importance of RAS mutations in personalized or precision medicine particularly in molecular targeted therapy, as well as their use as diagnostic and prognostic markers as therapeutic determinants in human cancers.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; HRAS; KRAS; Mutation; NRAS; Oncogene; Personalized medicine; Precision medicine

Mesh:

Substances:

Year:  2019        PMID: 31255772     DOI: 10.1016/j.semcancer.2019.06.007

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  25 in total

Review 1.  Targeting Mutated KRAS Genes to Treat Solid Tumours.

Authors:  Tharani Krishnan; Rachel Roberts-Thomson; Vy Broadbridge; Timothy Price
Journal:  Mol Diagn Ther       Date:  2021-12-16       Impact factor: 4.074

Review 2.  KRAS: A Druggable Target in Colon Cancer Patients.

Authors:  Francesca Negri; Lorena Bottarelli; Gian Luigi de'Angelis; Letizia Gnetti
Journal:  Int J Mol Sci       Date:  2022-04-08       Impact factor: 6.208

Review 3.  Emerging RAS-directed therapies for cancer.

Authors:  Michael Conroy; Darren Cowzer; Walter Kolch; Austin G Duffy
Journal:  Cancer Drug Resist       Date:  2021-04-08

4.  ERK2 Phosphorylates PFAS to Mediate Posttranslational Control of De Novo Purine Synthesis.

Authors:  Eunus S Ali; Umakant Sahu; Elodie Villa; Brendan P O'Hara; Peng Gao; Cynthia Beaudet; Antony W Wood; John M Asara; Issam Ben-Sahra
Journal:  Mol Cell       Date:  2020-06-01       Impact factor: 17.970

Review 5.  Anti-tumor effect of statin on pancreatic adenocarcinoma: From concept to precision medicine.

Authors:  Chung-Tsui Huang; Yao-Jen Liang
Journal:  World J Clin Cases       Date:  2021-06-26       Impact factor: 1.337

6.  Identification and Validation of T-cell Receptors Targeting RAS Hotspot Mutations in Human Cancers for Use in Cell-based Immunotherapy.

Authors:  Noam Levin; Biman C Paria; Nolan R Vale; Rami Yossef; Frank J Lowery; Maria R Parkhurst; Zhiya Yu; Maria Florentin; Gal Cafri; Jared J Gartner; Mackenzie L Shindorf; Lien T Ngo; Satyajit Ray; Sanghyun P Kim; Amy R Copeland; Paul F Robbins; Steven A Rosenberg
Journal:  Clin Cancer Res       Date:  2021-06-24       Impact factor: 13.801

Review 7.  A Driver Never Works Alone-Interplay Networks of Mutant p53, MYC, RAS, and Other Universal Oncogenic Drivers in Human Cancer.

Authors:  Maria Grzes; Magdalena Oron; Zuzanna Staszczak; Akanksha Jaiswar; Magdalena Nowak-Niezgoda; Dawid Walerych
Journal:  Cancers (Basel)       Date:  2020-06-11       Impact factor: 6.639

Review 8.  Targeting Aberrant RAS/RAF/MEK/ERK Signaling for Cancer Therapy.

Authors:  Ufuk Degirmenci; Mei Wang; Jiancheng Hu
Journal:  Cells       Date:  2020-01-13       Impact factor: 6.600

9.  MTDH promotes metastasis of clear cell renal cell carcinoma by activating SND1-mediated ERK signaling and epithelial-mesenchymal transition.

Authors:  Anbang He; Shiming He; Cong Huang; Zhicong Chen; Yucai Wu; Yanqing Gong; Xuesong Li; Liqun Zhou
Journal:  Aging (Albany NY)       Date:  2020-01-24       Impact factor: 5.682

Review 10.  Insights on CXC chemokine receptor 2 in breast cancer: An emerging target for oncotherapy.

Authors:  Fengzhu Guo; Lang Long; Jiantao Wang; Yuyi Wang; Yanyang Liu; Li Wang; Feng Luo
Journal:  Oncol Lett       Date:  2019-10-03       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.